These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 7778532)

  • 1. Fundamental role of angiotensin-converting enzyme inhibitors in the management of congestive heart failure.
    Opie LH
    Am J Cardiol; 1995 Jun; 75(18):3F-6F. PubMed ID: 7778532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing the treatment of heart failure.
    Giles TD
    Curr Opin Cardiol; 1994 Jul; 9 Suppl 1():S21-7. PubMed ID: 7827370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Congestive heart failure: what should be the initial therapy and why?
    Chatterjee K
    Am J Cardiovasc Drugs; 2002; 2(1):1-6. PubMed ID: 14727993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacoeconomic considerations in assessing and selecting congestive heart failure therapies.
    Levy E; Levy P
    Pharmacoeconomics; 2002; 20(14):963-77. PubMed ID: 12403637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical advances in the treatment of congestive heart failure.
    Armstrong PW; Moe GW
    Circulation; 1993 Dec; 88(6):2941-52. PubMed ID: 7902784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Should all patients with congestive heart failure and dilated cardiomyopathy be treated with vasodilators?
    Massie BM
    Cardiovasc Clin; 1990; 21(1):251-62; discussion 263-4. PubMed ID: 2199051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the flosequinan-ACE inhibitor trial (FACET).
    Massie BM; Berk MR; Brozena SC; Elkayam U; Plehn JF; Kukin ML; Packer M; Murphy BE; Neuberg GW; Steingart RM
    Circulation; 1993 Aug; 88(2):492-501. PubMed ID: 8339411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale and design of the third vasodilator-heart failure trial (V-HeFT III): felodipine as adjunctive therapy to enalapril and loop diuretics with or without digoxin in chronic congestive heart failure. V-HeFT III investigators.
    Boden WE; Ziesche S; Carson PE; Conrad CH; Syat D; Cohn JN
    Am J Cardiol; 1996 May; 77(12):1078-82. PubMed ID: 8644661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The multifacetted role of angiotensin converting enzyme inhibitors in congestive heart failure.
    Firth BG
    Am J Med Sci; 1988 Oct; 296(4):275-88. PubMed ID: 3057910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intractable heart failure despite angiotensin-converting enzyme inhibitors, digoxin, and diuretics: long-term effectiveness of add-on therapy with pimobendan.
    Hagemeijer F
    Am Heart J; 1991 Aug; 122(2):517-22. PubMed ID: 1858635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Left ventricular diastolic heart failure with normal left ventricular systolic function in older persons.
    Aronow WS
    J Lab Clin Med; 2001 May; 137(5):316-23. PubMed ID: 11329528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ACE inhibitors in congestive heart failure.
    Kantner TR
    J Fam Pract; 1992 Sep; 35(3):305-14. PubMed ID: 1517728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacologic treatment of chronic congestive heart failure].
    Halawa B
    Przegl Lek; 1996; 53(3):119-23. PubMed ID: 8754362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Trends in pharmacological treatment of congestive heart failure].
    Halawa B
    Pol Merkur Lekarski; 1999 Mar; 6(33):152-6. PubMed ID: 10365602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Digoxin and angiotensin-converting enzyme inhibitors in the treatment of chronic congestive heart failure].
    Thery C
    Therapie; 1994; 49(3):211-8. PubMed ID: 7878586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin-converting enzyme inhibitors in the clinical setting of chronic congestive heart failure.
    Reyes AJ
    Am J Cardiol; 1995 Jun; 75(18):50F-55F. PubMed ID: 7778535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin-converting enzyme inhibitors in heart failure: new strategies justified by recent clinical trials.
    Young JB
    Int J Cardiol; 1994 Feb; 43(2):151-63. PubMed ID: 8181869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing the treatment of congestive heart failure: diuretics, vasodilators, and angiotensin-converting enzyme inhibitors.
    Chow MS
    Pharmacotherapy; 1993; 13(5 Pt 2):82S-87S. PubMed ID: 8233997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Community pharmacist outreach program directed at physicians treating congestive heart failure.
    Turner CJ; Parfrey P; Ryan K; Miller R; Brown A
    Am J Health Syst Pharm; 2000 Apr; 57(8):747-52. PubMed ID: 10786260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased plasma level of substance P in patients with severe congestive heart failure treated with ACE inhibitors.
    Valdemarsson S; Edvinsson L; Ekman R; Hedner P; Sjöholm A
    J Intern Med; 1991 Oct; 230(4):325-31. PubMed ID: 1717629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.